Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Personalized medicine in multiple sclerosis: hope or reality?
Phosphodiesterase 5 inhibition at disease onset prevents experimental autoimmune encephalomyelitis progression through immunoregulatory and neuroprotective actions.
Cerebral lesions of multiple sclerosis: is gadolinium always irreplaceable in assessing lesion activity?
Possible induction of acute disseminated encephalomyelitis (ADEM)-like demyelinating illness by intrathecal mesenchymal stem cell injection.
From genes to characteristics of multiple sclerosis.
Therapeutic inhibition of the alternative complement pathway attenuates chronic EAE.
Frequent early multiple sclerosis relapses during treatment with fingolimod: a paradoxical effect?
Supporting work for people with multiple sclerosis.
Core outcome measures for exercise studies in people with multiple sclerosis: recommendations from a multidisciplinary consensus meeting.
Hypomethylating Agent 5-Aza-2'-deoxycytidine (DAC) Ameliorates Multiple Sclerosis in Mouse Models.
Interferon beta assessment in non-Chinese and Chinese subjects: Pharmacokinetics and pharmacodynamic activity of an endogenous cytokine are not race dependent.
Drug therapy for multiple sclerosis.
Common mechanisms in neurodegeneration and neuroinflammation: a BrainNet Europe gene expression microarray study.
Correlation of midkine serum level with pro- and anti-inflamatory cytokines in multiple sclerosis.
C-11Utility of the Ten Item Personality Inventory (TIPI) in Multiple Sclerosis (MS): What Can 10 Items Tell Us?
The Impact of Interferon Beta and Natalizumab on Comorbid Migraine in Multiple Sclerosis.
A new therapeutic target for the treatment of multiple sclerosis.
Role of early viral infections in development of multiple sclerosis.
Conventional and Advanced Imaging in Neuromyelitis Optica.
Beneficial effects of Rituximab in patients with anti-MAG (myelin-associated glycoprotein) neuropathy: case reports.
Improving the quality of mental health care in Multiple Sclerosis.
Risk genes associated with pediatric-onset MS but not with monophasic acquired CNS demyelination.
Over-the-counter anti-oxidant therapies for use in multiple sclerosis: A systematic review.
Long-term treatment of relapsing-remitting multiple sclerosis with interferon β: how strongly should we encourage patients to adhere to the 'old' therapies?
VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses.

Pages